Comprehensive genomic profiling testing in Japanese castration-resistant prostate cancer patients: results of a single-center retrospective cohort study

被引：1

作者：

Fukushima, Takafumi ^{[1
]}

Goto, Keisuke ^{[1
]}

Hayashi, Tetsutaro ^{[1
]}

Ikeda, Kenichiro ^{[1
]}

Hatayama, Tomoya ^{[1
]}

Yamanaka, Ryoken ^{[1
]}

Iwane, Kyosuke ^{[1
]}

Tasaka, Ryo ^{[1
]}

Kohada, Yuki ^{[1
]}

Takemoto, Kenshiro ^{[1
]}

Kobatake, Kohei ^{[1
]}

Goriki, Akihiro ^{[1
]}

Toshida, Asuka ^{[2
]}

Nakahara, Hikaru ^{[2
]}

Motonaga, Masanori ^{[3
]}

Tokumo, Kentaro ^{[4
]}

Fujii, Yasutoshi ^{[4
,5
]}

Hayes, C. Nelson ^{[5
]}

Okamoto, Wataru ^{[6
]}

Kubo, Toshio ^{[7
]}

Matsumoto, Takashi ^{[8
]}

Shiota, Masaki ^{[8
]}

Yamamoto, Noboru ^{[9
]}

Urabe, Yuji ^{[10
]}

Hiyama, Eiso ^{[11
,12
]}

Arihiro, Koji ^{[13
]}

Hinoi, Takao ^{[2
]}

Hinata, Nobuyuki ^{[1
]}

机构：

[1] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Urol, 1-2-3 Kasumi,Minamiku, Hiroshima 7348551, Japan

[2] Hiroshima Univ Hosp, Genom Med Ctr, Dept Clin & Mol Genet, Hiroshima, Japan

[3] Hiroshima Univ Hosp, Dept Pharmaceut Serv, Hiroshima, Japan

[4] Hiroshima Univ Hosp, Dept Clin Oncol, Hiroshima, Japan

[5] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Gastroenterol, Hiroshima, Japan

[6] Hiroshima Univ Hosp, Canc Treatment Ctr, Hiroshima, Japan

[7] OkayamaUnivers Hosp, Ctr Clin Oncol, Okayama, Japan

[8] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka, Japan

[9] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan

[10] Hiroshima Univ Hosp, Dept Gastrointestinal Endoscopy & Med, Hiroshima, Japan

[11] Hiroshima Univ Hosp, Dept Pediat Surg, Hiroshima, Japan

[12] Hiroshima Univ, Nat Sci Ctr Basic Res & Dev, Hiroshima, Japan

[13] Hiroshima Univ Hosp, Dept AnatomicalPathol, Hiroshima, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 54卷 / 02期

关键词：

castration-resistant prostate cancer; comprehensive genome profiling testing; next-generation sequencing; CDK12; chemotherapy; POSITIVE SOLID TUMORS; INCREASED SURVIVAL; DOCETAXEL; PREDNISOLONE; MITOXANTRONE; ABIRATERONE;

D O I：

10.1093/jjco/hyad148

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective Comprehensive genomic profiling testing using a hybrid-capture next-generation sequencing is commonly used in clinical practice to employ precision medicine in cancer treatment worldwide. In this study, we aimed to analyze the profiles obtained using comprehensive genomic profiling testing that was performed in Japanese castration-resistant prostate cancer patients and to discuss the genetic findings in a real-world setting.Methods A total of 60 cases and 57 castration-resistant prostate cancer patients underwent comprehensive genomic profiling testing between 1 January 2021 and 31 December 2022. Four types of comprehensive genomic profiling testing were selected, and clinically significant cancer-specific gene alterations were identified.Results The median age of patients was 74 years, and the median prostate-specific antigen value at the time of submission was 18.6 ng/ml. Fifty-seven (95%) of 60 cases were metastatic castration-resistant prostate cancers, and 3 cases (5%) were non-metastatic. Among all genetic alterations, androgen-receptor alteration was the most frequently detected in 17 cases (28.3%), followed by 15 cases of TP53 (25.0%), 14 cases of CDK12 (23.3%), 10 cases of phosphatase and tensin homolog (16.7%) and 9 cases of ATM (15.0%) mutations. A total of 13 patients (21.7%) received systemic therapy according to the comprehensive genomic profiling testing results. Overall, the survival rate was significantly greater in the group treated through systemic therapy based on comprehensive genomic profiling testing compared with the group without new therapeutic treatment (P = 0.041).Conclusions Comprehensive genomic profiling testing is recommended in castration-resistant prostate cancer patients identified as resistant to standard therapy as this can provide a new therapeutic option. Comprehensive genomic profiling testing is useful for the selection of treatment for Japanese patients with castration-resistant prostate cancer.

引用

页码：175 / 181

页数：7

共 50 条

[21] Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan
Fukuta, Fumimasa
Kitamura, Hiroshi
Yanase, Masahiro
Taguchi, Keisuke
Takahashi, Atsushi
Kunishima, Yasuharu
Miyake, Masafumi
Adachi, Hideki
Itoh, Naoki
Hirose, Takaoki
Takagi, Seiji
Miyao, Noriomi
Matsukawa, Masanori
Shigyo, Masanori
Masumori, Naoya
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (07) : 682 - 687
[22] Safety and efficacy of cabazitaxel in Japanese patients with castration-resistant prostate cancer
Yamamoto, Teppei
Ishizuka, Osamu
Oike, Hiroshi
Shiozaki, Masashi
Haba, Tomomi
Oguchi, Tomohiko
Iijima, Kazuyoshi
Kato, Haruaki
PROSTATE INTERNATIONAL, 2020, 8 (01) : 27 - 33
[23] A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer
Seisen, Thomas
Roupret, Morgan
Gomez, Florie
Malouf, Gabriel G.
Shariat, Shahrokh F.
Peyronnet, Benoit
Spano, Jean-Philippe
Cancel-Tassin, Geraldine
Cussenot, Olivier
CANCER TREATMENT REVIEWS, 2016, 48 : 25 - 33
[24] Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer: Results of a Compassionate Use Program in The Netherlands
Wissing, Michel D.
van Oort, Inge M.
Gerritsen, Winald R.
van den Eertwegh, Alfons J. M.
Coenen, Jules L. L. M.
Bergman, Andries M.
Gelderblom, Hans
CLINICAL GENITOURINARY CANCER, 2013, 11 (03) : 238 - +
[25] Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer
Kato, Haruo
Furuya, Yosuke
Miyazawa, Yoshiyuki
Miyao, Takeshi
Syuto, Takahiro
Nomura, Masashi
Sekine, Yoshitaka
Koike, Hidekazu
Matsui, Hiroshi
Shibata, Yasuhiro
Ito, Kazuto
Suzuki, Kazuhiro
ANTICANCER RESEARCH, 2016, 36 (11) : 6141 - 6149
[26] Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Menssouri, Naoual
Poiraudeau, Loic
Helissey, Carole
Bigot, Ludovic
Sabio, Jonathan
Ibrahim, Tony
Pobel, Cedric
Nicotra, Claudio
Ngo-Camus, Maud
Lacroix, Ludovic
Rouleau, Etienne
Tselikas, Lambros
Chauchereau, Anne
Blanc-Durand, Felix
Bernard-Tessier, Alice
Patrikidou, Anna
Naoun, Natacha
Flippot, Ronan
Colomba, Emeline
Fuerea, Alina
Albiges, Laurence
Lavaud, Pernelle
van de Wiel, Paul
den Biezen, Eveline
Wesseling-Rozendaal, Yvonne
Ponce, Santiago
Michiels, Stefan
Massard, Christophe
Gautheret, Daniel
Barlesi, Fabrice
Andre, Fabrice
Besse, Benjamin
Scoazec, Jean-Yves
Friboulet, Luc
Fizazi, Karim
Loriot, Yohann
CLINICAL CANCER RESEARCH, 2023, 29 (21) : 4504 - 4517
[27] The Current Status of Comprehensive Genomic Profiling in the Management of Metastatic Castration-Resistant Prostate Cancer: A Study from a Cooperative Hospital for Cancer Genomic Medicine in Japan
Akatsuka, Jun
Kimura, Go
Takadate, Mami
Hiraoka, Sayuri
Sahara, Tomoko
Iwai, Takuma
Hasegawa, Hiroya
Mikami, Hikaru
Obayashi, Kotaro
Takeda, Hayato
Endo, Yuki
Toyama, Yuka
Yamamoto, Yoichiro
Yamada, Takeshi
Kondo, Yukihiro
JOURNAL OF NIPPON MEDICAL SCHOOL, 2024, 91 (05)
[28] Abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer: a real-world retrospective study in China
Liu, Min
Yan, Jiaqing
Le, Kaidi
Li, Ying
Xing, Nianzeng
Li, Guohui
FRONTIERS IN ENDOCRINOLOGY, 2023, 14
[29] Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database
Delanoy, Nicolas
Hardy-Bessard, Anne-Claire
Efstathiou, Eleni
Le Moulec, Sylvestre
Basso, Umberto
Birtle, Alison
Thomson, Alastair
Krainer, Michael
Guillot, Aline
De Giorgi, Ugo
Hasbini, Ali
Daugaard, Gedske
Bahl, Amit
Chowdhury, Simon
Caffo, Orazio
Beuzeboc, Philippe
Spaeth, Dominique
Eymard, Jean-Christophe
Flechon, Aude
Alexandre, Jerome
Helissey, Carole
Butt, Mohamed
Priou, Frank
Lechevallier, Eric
Deville, Jean-Laurent
Goupil, Marine Gross
Morales, Rafael
Thiery-Vuillemin, Antoine
Gavrikova, Tatiana
Barthelemy, Philippe
Sella, Avishay
Fizazi, Karim
Baciarello, Giulia
Fererro, Jean-Marc
Laguerre, Brigitte
Verret, Benjamin
Hans, Sophie
Oudard, Stephane
EUROPEAN UROLOGY ONCOLOGY, 2018, 1 (06): : 467 - 475
[30] Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study
Gacci, Mauro
Marchioni, Michele
De Francesco, Piergustavo
Natoli, Clara
Calabro, Fabio
Losanno, Tania
Gianmartin, Cito
Serni, Sergio
Doni, Laura
De Nunzio, Cosimo
De Tursi, Michele
Valeriani, Maurizio
Giacinti, Silvana
Alvarez-Maestro, Mario
Scarcia, Marcello
Ludovico, Giuseppe M.
Del Bene, Gabriella
Simone, Giuseppe
Ferriero, Mariaconsiglia
Tuderti, Gabriele
Bove, Pierluigi
Laudisi, Anastasia
Carrieri, Giuseppe
Cormio, Luigi
Verze, Paolo
La Rocca, Roberto
Falsaperla, Mario
Frantellizzi, Viviana
Greco, Francesco
Di Nicola, Marta
Schips, Luigi
Cindolo, Luca
MINERVA UROLOGY AND NEPHROLOGY, 2021, 73 (04): : 489 - 497

← 1 2 3 4 5 →